Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Human Paratuberculosis Foundation is a non-profit organization dedicated to investigating the role of Mycobacterium avium subspecies paratuberculosis (MAP) in human diseases, primarily Crohn's disease. The foundation facilitates research, provides education, and advocates for the development of effective diagnostics and treatments targeting MAP infections. By collaborating with scientists and clinicians globally, the organization aims to bridge the gap between veterinary and human medicine regarding paratuberculosis. Their work focuses on validating MAP as a human pathogen and supporting clinical trials for anti-mycobacterial therapies. The foundation also provides resources for patients and healthcare providers to better understand the potential infectious etiology of autoimmune conditions. It plays a crucial role in funding pilot studies and organizing international conferences to advance the MAP research field.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Human Paratuberculosis Foundation.